Patrick Fisher, President of Global Limb Recon at Orthofix Medical Inc., filed a Form 4 on November 4, 2026, disclosing a sale of 150 shares of common stock on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Patrick Fisher, serving as President, Global Limb Recon at Orthofix Medical Inc. (NASDAQ:OFIX)
  • Transaction: 150 shares of common stock disposed of (transaction code S) on November 2, 2026, at $9.07 per share
  • Trading plan: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Fisher on May 29, 2026
  • Remaining holdings: Fisher beneficially owned 50,769 shares following the reported transaction, held directly
  • Restricted stock units: The post-transaction total includes 36,028 previously reported restricted stock units

Fisher's Rule 10b5-1 Sale of Orthofix Common Stock

According to the filing, Patrick Fisher, an officer of Orthofix Medical Inc. with the title President, Global Limb Recon, disposed of 150 shares of Orthofix common stock on November 2, 2026, at a price of $9.07 per share. The transaction was coded "S," indicating a sale, and the form confirms it was executed under a Rule 10b5-1 trading plan that Fisher adopted on May 29, 2026. The filing notes the box indicating a transaction made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c) has been checked.

Following the reported transaction, the filing states that Fisher directly beneficially owns 50,769 shares of Orthofix common stock. The filing further discloses that this total includes 36,028 previously reported restricted stock units. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was signed by J. Andres Cedron as attorney-in-fact on behalf of Fisher, and was filed with the SEC on November 4, 2026. The filing lists Fisher's address as 3451 Plano Parkway, Lewisville, Texas 75056. No amendment to a prior filing was indicated.

What Was Disclosed

The filing disclosed a single sale of 150 shares of Orthofix Medical Inc. common stock by officer Patrick Fisher on November 2, 2026, at $9.07 per share, conducted under a pre-established Rule 10b5-1 plan, leaving Fisher with 50,769 shares directly held.